- Email: [email protected]
4920211 Mutated adenovirus E1A gene for E1A promoter stimulation
PATENT ABSTRACTS
602
tivation which comprises transformation of a host bacterium having a defect in a chromosomal gene needed for the synthesis or maintenance of the cell envelope with an extrachromosomal element capable of complementing the chromosomal gene defect of the host bacterium, the extra-chromosomal element also including an expressible DNA-sequenee coding for a desired product.
4920054 SHUTTLE VECTORS FROM RHODOCOCCUS EQUI Maya Kozlowski, Wayne Glasse-Davies, Brampton, Canada assigned to Allelix Inc Recombinant D N A plasmids capable of functioning as shuttle vectors in Rhodococcus equi, Corynebacterium, E. coli, B. subtilis, or S. aureus are disclosed. The recombinant plasmid contains an origin of replication which is functional in Rhodococcus and at least one of E. coil, Corynebacterium, S. aureus, and B. subtilis. Additionally, the plasmid contains a heritable, selectable marker.
A functional mutated E1A gene of human adenovirus subgroup B: ! is provided which has a modified autorepression functional domain that is effective to express EIA products that stimulate without net repression of promoters controlling an EIA mutated gene.
4920213 METHOD AND COMPOSITIONS USEFUL IN PREVENTING EQUINE INFLUENZA Beverl Dale, Barbara Cordell assigned to Biotechnology Research Partners Ltd Recombinant vaccines for immunizing horses against equine influenza virus (EIV) are disclosed. The DNA sequences encoding the hemagglutinin (HA) and neuraminidase (NA) glycoproteins from the two strains of EIV currently infective in horses are used to construct vaccinia carried vaccines, to design synthetic peptides for primer and booster administration, and to permit recombinant synthesis of HA and/or NA protein based vaccines. These DNA sequences also provide probes useful for preparing similar vaccines from fresh isolates of new strains generated by genetic drift.
4920209 ORAL VACCINES Alan R Davis, Paul P Hung assigned to American Home Products Corporation Methods and vaccines for the production of antibodies to infectious organisms are described. Live recombinant adenovirus containing a foreign gene coding for an antigen produced by another infectious organism is delivered to the intestine of a warm-blooded animal in an enteric-coated dosage form, whereupon the virus infects the gut wall and induces the production of antibodies or cell mediated immunity to both adenovirus and the other infectious organism.
4920211 MUTATED ADENOVIRUS EIA GENE FOR E1A PROMOTER STIMULATION Clark Tibbetts, Pamela L Larsen assigned to Vanderbilt University
4921757 SYSTEM FOR DELAYED AND PULSED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES Margaret Whcatley, Robert Langer, Herman Eisen assigned to Massachusetts Institute of Technology A system for controlled release both in vivo and in vitro of entrapped substances, either at a constant rate over a period of time or in discrete pulses, is disclosed. Biologically active substances, such as drugs, hormones, enzymes, genetic material, antigens including viruses, vaccines, or inorganic material such as dyes and nutrients, are entrapped in liposomes which are protected from the biological environment by encapsulation within semi-permeable microcapsules or a permeable polymeric matrix. Release of the entrapped substance into the surrounding environment is governed by the permeability of both the liposome and surrounding matrix to the substance. Permeability of the lipo-
602
tivation which comprises transformation of a host bacterium having a defect in a chromosomal gene needed for the synthesis or maintenance of the cell envelope with an extrachromosomal element capable of complementing the chromosomal gene defect of the host bacterium, the extra-chromosomal element also including an expressible DNA-sequenee coding for a desired product.
4920054 SHUTTLE VECTORS FROM RHODOCOCCUS EQUI Maya Kozlowski, Wayne Glasse-Davies, Brampton, Canada assigned to Allelix Inc Recombinant D N A plasmids capable of functioning as shuttle vectors in Rhodococcus equi, Corynebacterium, E. coli, B. subtilis, or S. aureus are disclosed. The recombinant plasmid contains an origin of replication which is functional in Rhodococcus and at least one of E. coil, Corynebacterium, S. aureus, and B. subtilis. Additionally, the plasmid contains a heritable, selectable marker.
A functional mutated E1A gene of human adenovirus subgroup B: ! is provided which has a modified autorepression functional domain that is effective to express EIA products that stimulate without net repression of promoters controlling an EIA mutated gene.
4920213 METHOD AND COMPOSITIONS USEFUL IN PREVENTING EQUINE INFLUENZA Beverl Dale, Barbara Cordell assigned to Biotechnology Research Partners Ltd Recombinant vaccines for immunizing horses against equine influenza virus (EIV) are disclosed. The DNA sequences encoding the hemagglutinin (HA) and neuraminidase (NA) glycoproteins from the two strains of EIV currently infective in horses are used to construct vaccinia carried vaccines, to design synthetic peptides for primer and booster administration, and to permit recombinant synthesis of HA and/or NA protein based vaccines. These DNA sequences also provide probes useful for preparing similar vaccines from fresh isolates of new strains generated by genetic drift.
4920209 ORAL VACCINES Alan R Davis, Paul P Hung assigned to American Home Products Corporation Methods and vaccines for the production of antibodies to infectious organisms are described. Live recombinant adenovirus containing a foreign gene coding for an antigen produced by another infectious organism is delivered to the intestine of a warm-blooded animal in an enteric-coated dosage form, whereupon the virus infects the gut wall and induces the production of antibodies or cell mediated immunity to both adenovirus and the other infectious organism.
4920211 MUTATED ADENOVIRUS EIA GENE FOR E1A PROMOTER STIMULATION Clark Tibbetts, Pamela L Larsen assigned to Vanderbilt University
4921757 SYSTEM FOR DELAYED AND PULSED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES Margaret Whcatley, Robert Langer, Herman Eisen assigned to Massachusetts Institute of Technology A system for controlled release both in vivo and in vitro of entrapped substances, either at a constant rate over a period of time or in discrete pulses, is disclosed. Biologically active substances, such as drugs, hormones, enzymes, genetic material, antigens including viruses, vaccines, or inorganic material such as dyes and nutrients, are entrapped in liposomes which are protected from the biological environment by encapsulation within semi-permeable microcapsules or a permeable polymeric matrix. Release of the entrapped substance into the surrounding environment is governed by the permeability of both the liposome and surrounding matrix to the substance. Permeability of the lipo-